Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance

Tivantinib, also known as ARQ-197, is a potent non-ATP competitive selective c-Met inhibitor currently under phase 3 clinical trial evaluation for liver and lung cancers. In this study, we explored factors that may lead to tivantinib resistance, especially in regards to its interaction with ATP-bind...

Full description

Bibliographic Details
Main Authors: Zhuo-Xun Wu, Yuqi Yang, Qiu-Xu Teng, Jing-Quan Wang, Zi-Ning Lei, Jing-Qiu Wang, Sabrina Lusvarghi, Suresh V. Ambudkar, Dong-Hua Yang, Zhe-Sheng Chen
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cancers
Subjects:
atp-binding cassette (abc) transporter
tivantinib
arq-197
abcg2
drug transport
multidrug resistance (mdr)
Online Access:https://www.mdpi.com/2072-6694/12/1/186

Internet

https://www.mdpi.com/2072-6694/12/1/186

Similar Items